MedTrace Logo

Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay

NCT04240600 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2020-09-03

No results posted yet for this study

Summary

A randomized controlled clinical trial in two groups of supplementation with high protein enteral formula and a normocaloric enteral formula in two groups of 37 patients .

Conditions

  • Acute Myeloid Leukemia, Adult

Interventions

DIETARY_SUPPLEMENT

Experimental group

2 cans or bottles (200ml)per day, orally

DIETARY_SUPPLEMENT

Control group

2 cans or bottles (200ml)per day, orally

Sponsors & Collaborators

  • Fresenius Kabi

    collaborator INDUSTRY

  • Hospital General de Mexico

    lead OTHER_GOV

Principal Investigators

  • Vanessa Fuchs Tarlovsky, PhD · Hospital General de México

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-01-01
Completion
2021-12-01

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04240600 on ClinicalTrials.gov